EuroBiotech: More Articles of Note


> The FDA cleared BioLineRx to trial anti-cancer vaccine AGI-134 in solid tumors. The action sets BioLineRx up to expand the trial beyond the U.K. and Israel by opening sites in the U.S. in the first half of next year. Release 

> eTheRNA immunotherapies opened a new research base in Ghent, Belgium. The site will house the biotech’s enlarged research and preclinical teams. Statement 

> Sylentis presented new data from its failed phase 3 dry eye disease trial. The analysis linked siRNA drug tivanisiran to statistically significant improvements in patients with Sjögren's syndrome. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> BerGenBio completed enrollment into the second stage of a phase 2 lung cancer trial that is testing AXL inhibitor bemcentinib in combination with Merck’s Keytruda. Statement 

> OMass Therapeutics appointed Rosamond Deegan as CEO. Deegan joins OMass from Bicycle Therapeutics, where she served as chief business officer. Release 

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.